Aliases & Classifications for Morbid Obesity

MalaCards integrated aliases for Morbid Obesity:

Name: Morbid Obesity 38 12 29 6 15
Obesity, Morbid 44 73
Severe Obesity 12
Obesity Morbid 55

Classifications:



External Ids:

Disease Ontology 12 DOID:11981
ICD9CM 35 278.01
MeSH 44 D009767
NCIt 50 C34858
UMLS 73 C0028756

Summaries for Morbid Obesity

MalaCards based summary : Morbid Obesity, also known as obesity, morbid, is related to nonalcoholic steatohepatitis and acanthosis nigricans, and has symptoms including obesity, metabolically benign An important gene associated with Morbid Obesity is PPARG (Peroxisome Proliferator Activated Receptor Gamma), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Dexmedetomidine and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and bone, and related phenotypes are adipose tissue and behavior/neurological

Related Diseases for Morbid Obesity

Diseases related to Morbid Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 nonalcoholic steatohepatitis 30.7 ADIPOQ INS LEP
2 acanthosis nigricans 30.0 ADIPOQ INS LEP PPARG
3 sleep disorder 29.7 CRP HCRT LEP
4 gastroesophageal reflux 29.6 CCK GCG GHRL PYY
5 apnea, obstructive sleep 29.5 ADIPOQ CRP HCRT INS LEP
6 fatty liver disease 29.2 ADIPOQ INS LEP LEPR PPARG RETN
7 myocardial infarction 28.9 ADIPOQ CRP GHRL INS RETN
8 diabetes mellitus 28.8 ADIPOQ ADRB3 CRP GCG INS LEP
9 acute pancreatitis 28.6 CCK CRP LPL
10 pancreatitis 28.4 CCK CRP LPL
11 sleep apnea 28.0 ADIPOQ CRP GHRL HCRT INS LEP
12 eating disorder 27.8 ADIPOQ CCK GHRL LEP LEPR MC4R
13 anorexia nervosa 26.3 ADIPOQ CCK GHRL HCRT LEP LEPR
14 prader-willi syndrome 26.2 ADIPOQ CCK GHRL HCRT INS LEP
15 diabetes mellitus, noninsulin-dependent 23.8 ADIPOQ ADRB3 CRP FABP2 GCG GHRL
16 body mass index quantitative trait locus 11 20.1 ADIPOQ ADRB3 CCK CRP FABP2 FTO
17 morbid obesity and spermatogenic failure 12.5
18 leptin deficiency or dysfunction 11.6
19 leptin receptor deficiency 11.3
20 malignant otitis externa 10.8 CRP INS
21 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.6 CRP INS LEP
22 familial partial lipodystrophy 10.6 INS LEP PPARG
23 type 1 diabetes mellitus 15 10.6 GCG INS
24 idiopathic edema 10.6 ADIPOQ INS PPARG
25 acquired generalized lipodystrophy 10.6 ADIPOQ LEP RETN
26 obesity-hypoventilation syndrome 10.6 ADIPOQ LEP RETN
27 idiopathic recurrent pericarditis 10.6 ADIPOQ LEP RETN
28 lipodystrophy, familial partial, type 2 10.6 INS LEP
29 autoinflammation, lipodystrophy, and dermatosis syndrome 10.5 ADIPOQ CRP PPARG
30 coronary artery aneurysm 10.5 ADIPOQ LEP RETN
31 nutritional deficiency disease 10.5 CRP GHRL LEP
32 acute insulin response 10.5 CRP GCG INS
33 abdominal obesity-metabolic syndrome 1 10.5 ADIPOQ INS LEP PPARG
34 acalculous cholecystitis 10.5 CCK CRP
35 hyperthyroidism 10.4 GHRL INS LEP
36 hyperuricemia 10.4 ADRB3 CRP INS
37 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.4 ADIPOQ INS
38 inherited metabolic disorder 10.4 ADIPOQ CRP INS LEP
39 atherosclerosis susceptibility 10.3 ADIPOQ CRP INS PPARG
40 postgastrectomy syndrome 10.3 INS PYY
41 arteriosclerosis 10.3 ADIPOQ CRP INS PPARG
42 chronic kidney failure 10.3 ADIPOQ CRP INS LEP
43 endocrine pancreas disease 10.3 ADIPOQ GCG INS LEP
44 hyperinsulinism 10.3 GHRL INS LEP
45 intestinal disease 10.3 CRP GCG GHRL
46 dumping syndrome 10.2 GCG INS PYY
47 arteries, anomalies of 10.2 ADIPOQ CRP INS LEP PPARG
48 jejunoileitis 10.1
49 duodenitis 10.1
50 severe pre-eclampsia 10.1 ADIPOQ LEP LEPR

Graphical network of the top 20 diseases related to Morbid Obesity:



Diseases related to Morbid Obesity

Symptoms & Phenotypes for Morbid Obesity

UMLS symptoms related to Morbid Obesity:


obesity, metabolically benign

MGI Mouse Phenotypes related to Morbid Obesity:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.37 ADIPOQ ADRB3 CEP19 FABP2 FTO GHRL
2 behavior/neurological MP:0005386 10.32 PPARG PYY ADIPOQ ADRB3 CCK CEP19
3 homeostasis/metabolism MP:0005376 10.32 ADRB3 CCK CEP19 CRP FABP2 FTO
4 growth/size/body region MP:0005378 10.25 ADIPOQ ADRB3 CEP19 FABP2 FTO HCRT
5 cardiovascular system MP:0005385 10.11 LEP LEPR LPL MC4R PPARG ADIPOQ
6 endocrine/exocrine gland MP:0005379 10.09 ADIPOQ ADRB3 CCK FTO GHRL INS
7 immune system MP:0005387 10.02 ADIPOQ CRP FTO INS LEP LEPR
8 liver/biliary system MP:0005370 9.96 ADIPOQ FABP2 FTO INS LEP LEPR
9 muscle MP:0005369 9.7 ADIPOQ HCRT INS LEP LEPR LPL
10 renal/urinary system MP:0005367 9.56 FABP2 FTO INS LEP LEPR PPARG
11 skeleton MP:0005390 9.28 ADIPOQ FTO INS LEP LEPR MC3R

Drugs & Therapeutics for Morbid Obesity

Drugs for Morbid Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 338)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 44475014
3
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
4
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Dalteparin Approved Phase 4 9005-49-6
7
Enoxaparin Approved Phase 4,Phase 1,Phase 2 9005-49-6 772
8
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
9 Nadroparin Approved, Investigational Phase 4 9041-08-1
10
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
11
Rocuronium Approved Phase 4,Phase 2,Not Applicable 119302-91-9, 143558-00-3 441290
12
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
13
Liraglutide Approved Phase 4,Not Applicable 204656-20-2 44147092
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
15
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
16
Methylene blue Approved, Investigational Phase 4,Phase 1,Phase 2 61-73-4
17
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
18
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
19
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
20
chenodeoxycholic acid Approved Phase 4,Phase 2,Phase 1 474-25-9 10133
21
Ursodeoxycholic acid Approved, Investigational Phase 4,Not Applicable 128-13-2 31401
22
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
23
Iron Approved Phase 4,Phase 2,Phase 3,Not Applicable 7439-89-6 23925
24
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
25
Ibuprofen Approved Phase 4 15687-27-1 3672
26
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
27
Verapamil Approved Phase 4 52-53-9 2520
28
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
29
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
30
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
31
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
32
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
33
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
34
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
36
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 13422-55-4
37
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
38 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
40 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Adrenergic Agents Phase 4,Phase 3,Phase 1,Not Applicable
42 Adrenergic Agonists Phase 4
43 Adrenergic alpha-2 Receptor Agonists Phase 4
44 Adrenergic alpha-Agonists Phase 4
45 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 1,Not Applicable,Early Phase 1
47 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Hypnotics and Sedatives Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 560)
# Name Status NCT ID Phase Drugs
1 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
2 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
3 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
6 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Unknown status NCT02206256 Phase 4 Omega-3 fatty acid capsules
7 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
8 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
9 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
10 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
11 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
12 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
13 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
14 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
15 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
16 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
17 Surgical Conditions During Laparoscopic Bariatric Surgery Completed NCT02703909 Phase 4 Rocuronium
18 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
19 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
20 Garcinia Mangostana Extracts in the Management of Weight Loss Completed NCT02823561 Phase 4
21 Population PK/PD of Propofol in the Morbidly Obese Patient Completed NCT00395681 Phase 4 Diprivan
22 Preoperative Condition in Giant Obese Patients Completed NCT02616003 Phase 4 Liraglutide
23 Study to Compare the Bioavailability (Amount of Drug Reaching the Blood) of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity Completed NCT03378960 Phase 4 Omeprazole 20mg
24 Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Completed NCT02340247 Phase 4 Ursodeoxycholic Acid;Chenodeoxycholic Acid
25 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Completed NCT00608712 Phase 4 Esomeprazole
26 The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron Completed NCT02390921 Phase 4 Fisiogen Ferro Forte;Venofer
27 A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery Completed NCT02233400 Phase 4 Acetaminophen
28 Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery Completed NCT02778958 Phase 4 paracetamol;ibuprofen
29 Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
30 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
31 Dosing Obese With Noxafil® Under a Trial (DONUT) Recruiting NCT03246386 Phase 4 Posaconazole Injection [Noxafil] 300mg;Posaconazole Injection [Noxafil] 400mg
32 Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) Recruiting NCT02320604 Phase 4 Administration of study drug
33 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4 Anastrazole
34 Weight Loss With Risedronate for Bone Health Recruiting NCT03411902 Phase 4 Risedronate Sodium 150 MG
35 DPE Technique in Labor Epidural for Morbidly Obese Women Recruiting NCT03074695 Phase 4 Dural puncture epidural (DPE);Standard Epidural (EPL)
36 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
37 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
38 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Recruiting NCT01913392 Phase 4
39 Ketamine for Pain Relief in Bariatric Surgery Recruiting NCT03052673 Phase 4 Fentanyl;ketamine
40 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Active, not recruiting NCT02374632 Phase 4
41 Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery Withdrawn NCT00361985 Phase 4 Esomeprazole;Esomeprazole
42 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
43 Bariatric Arterial Embolization for Morbid Obesity Unknown status NCT02786108 Phase 3
44 Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial Unknown status NCT02077517 Phase 3
45 Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients Unknown status NCT01279499 Phase 2, Phase 3 Sevoflurane;Sevoflurane;Propofol- Remifentanyl;Propofol, Remifentanyl
46 Transoral Gastroplasty for the Treatment of Morbid Obesity Unknown status NCT00661245 Phase 3
47 Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients Unknown status NCT01629394 Phase 2, Phase 3 Sugammadex;Sugammadex;Neostigmine;Neostigmine;Sugammadex;Sugammadex;Neostigmine;Neostigmine
48 The Effects of Exenatide After Gastric Restriction Unknown status NCT00872378 Phase 2, Phase 3 Exenatide;Placebo
49 Ketamine in Bariatric Surgery Unknown status NCT01724983 Phase 3 ketamine;fentanyl
50 Laryngeal Masks for Bariatric Surgery Unknown status NCT01724970 Phase 3

Search NIH Clinical Center for Morbid Obesity

Cochrane evidence based reviews: obesity, morbid

Genetic Tests for Morbid Obesity

Genetic tests related to Morbid Obesity:

# Genetic test Affiliating Genes
1 Morbid Obesity 29

Anatomical Context for Morbid Obesity

MalaCards organs/tissues related to Morbid Obesity:

41
Liver, Testes, Bone, Kidney, Brain, Thyroid, Lung

Publications for Morbid Obesity

Articles related to Morbid Obesity:

(show top 50) (show all 955)
# Title Authors Year
1
Reliability of International Classification of Diseases, Ninth Edition, Codes to Detect Morbid Obesity in Patients Undergoing Total Hip Arthroplasty. ( 29885969 )
2018
2
Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain. ( 29655552 )
2018
3
Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms. ( 29378512 )
2018
4
Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity. ( 29649379 )
2018
5
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. ( 29340679 )
2018
6
The trends and prevalence of obesity and morbid obesity among Australian school-aged children, 1985-2014. ( 29667237 )
2018
7
Effect of Manual Caudal and Downward Displacement of Lower Cervical Adipose Tissue on Laryngoscopic Grade of Patients with Morbid Obesity. ( 29868457 )
2018
8
The impact of living with morbid obesity on psychological need frustration: A study with bariatric patients. ( 29790653 )
2018
9
Abdominal Pain After Roux-En-Y Gastric Bypass for Morbid Obesity. ( 29739280 )
2018
10
Single Incision Versus Conventional Laparoscopic Sleeve Gastrectomy for Morbid Obesity: A Meta-Analysis. ( 29389227 )
2018
11
Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. ( 29271279 )
2018
12
A Tuscan general with morbid obesity. ( 29404906 )
2018
13
Cost-Effectiveness Analysis of Bariatric Surgery for Morbid Obesity. ( 29335933 )
2018
14
Weight Loss Surgery Reduces Healthcare Resource Utilization and All-Cause Inpatient Mortality in Morbid Obesity: a Propensity-Matched Analysis. ( 29931480 )
2018
15
Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation and fibrosis. ( 29878845 )
2018
16
Systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. ( 29735347 )
2018
17
Morbid obesity and functional status as predictors of surgical complication after renal transplantation. ( 28622834 )
2018
18
A perioperative care map improves outcomes in patients with morbid obesity undergoing major surgery. ( 29195738 )
2018
19
Effects of multidisciplinary interventions on weight loss and health outcomes in children and adolescents with morbid obesity. ( 29701298 )
2018
20
Morbid obesity: potential effects of hormonal contraception. ( 29777662 )
2018
21
Lower Extremity Geometry in Morbid Obesity-Considerations for Total Knee Arthroplasty. ( 29705683 )
2018
22
Comment on: systematic assessment of decision analytic models for the cost-effectiveness of bariatric surgery for morbid obesity. ( 29703504 )
2018
23
Associations of Prepregnancy Morbid Obesity and Prenatal Depression with Gestational Weight Gain. ( 29298365 )
2018
24
Remission of Sjogren's Syndrome after Roux-en-Y Gastric Bypass for Morbid Obesity. ( 29248981 )
2018
25
Brown adipose tissue lipid metabolism in morbid obesity: Effect of bariatric surgery-induced weight loss. ( 29377423 )
2018
26
Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow. ( 29352513 )
2018
27
Stomach Intestinal Pylorus-Sparing Surgery for Morbid Obesity. ( 29398898 )
2018
28
Influence of <i>FTO</i> rs9939609 polymorphism on appetite, ghrelin, leptin, IL6, TNFI+ levels, and food intake of women with morbid obesity. ( 29785132 )
2018
29
Influence of Drain Placement on Postoperative Pain Following Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity: Randomized Controlled Trial. ( 29971581 )
2018
30
Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study. ( 29271568 )
2018
31
Effect of Morbid Obesity on Midurethral Sling Efficacy for the Management of Stress Urinary Incontinence. ( 29734200 )
2018
32
Characterization of Metabolomic Profile Associated with Metabolic Improvement after Bariatric Surgery in Subjects with Morbid Obesity. ( 29893570 )
2018
33
Acute complications following endoscopic intragastric balloon insertion for treatment of morbid obesity in elderly patients. A single center experience. ( 29658677 )
2018
34
Biting the Hands that Feed &amp;quot;the Alligators&amp;quot;: A Case Study in Morbid Obesity Extremes, End-of-Life Care, and Prohibitions on Harming and Accelerating the End of Life. ( 29764322 )
2018
35
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. ( 29340676 )
2018
36
Morbid obesity is not a contraindication to transport on extracorporeal support. ( 29253111 )
2017
37
Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy for morbid obesity. ( 28069786 )
2017
38
Pulse-contour derived cardiac output measurements in morbid obesity: influence of actual, ideal and adjusted bodyweight. ( 28822023 )
2017
39
The usage of fasting glucose and glycated hemoglobin for the identification of unknown type 2 diabetes in high risk patients with morbid obesity. ( 28715238 )
2017
40
Answer to the Letter to the Editor Concerning &amp;quot;Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism&amp;quot;. ( 28840448 )
2017
41
Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. ( 28680646 )
2017
42
Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism. ( 28560524 )
2017
43
Long-Term Follow-Up of Autonomic and Enteric Measures in Patients Undergoing Vertical Banded Gastroplasty for Morbid Obesity. ( 28912907 )
2017
44
Perioperative Course, Weight Loss and Resolution of Comorbidities After Primary Sleeve Gastrectomy for Morbid Obesity: Are There Differences Between Adolescents and Adults? ( 28293902 )
2017
45
Epicardial fat thickness correlates with P-wave duration, left atrial size and decreased left ventricular systolic function in morbid obesity. ( 28739186 )
2017
46
Zinc Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27885534 )
2017
47
Intake of non-nutritive sweeteners is associated with an unhealthy lifestyle: a cross-sectional study in subjects with morbid obesity. ( 29299330 )
2017
48
Colon adenocarcinoma after jejunoileal bypass for morbid obesity. ( 29230281 )
2017
49
Anastomotic Stricture Rates Following Roux-en-Y Gastric Bypass for Morbid Obesity: A Comparison Between Linear and Circular-Stapled Anastomosis. ( 29237132 )
2017
50
Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. ( 28077498 )
2017

Variations for Morbid Obesity

ClinVar genetic disease variations for Morbid Obesity:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh37 Chromosome 3, 12422848: 12422848
2 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh38 Chromosome 3, 12381349: 12381349

Expression for Morbid Obesity

LifeMap Discovery
Genes differentially expressed in tissues of Morbid Obesity patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Skeletal Muscle - 5.09 0.006
2 SLN sarcolipin Skeletal Muscle - 4.64 0.007
Search GEO for disease gene expression data for Morbid Obesity.

Pathways for Morbid Obesity

Pathways related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 ADRB3 CCK GCG GHRL HCRT INS
2
Show member pathways
13.41 ADIPOQ ADRB3 GCG INS LEP LEPR
3
Show member pathways
12.92 ADRB3 CCK GCG GHRL HCRT LEP
4 12.34 ADIPOQ FTO GCG INS PPARG
5
Show member pathways
12.22 ADIPOQ INS LEP LEPR PPARG
6
Show member pathways
12.07 GCG GHRL INS LEP
8 11.94 ADRB3 GCG MC3R MC4R
9 11.58 INS LPL PPARG
10 11.54 ADIPOQ LEP LEPR
11 11.37 INS LEP LEPR
12 11.31 ADIPOQ FABP2 LPL PPARG
13 11.22 ADIPOQ INS LEP LPL PPARG RETN
14
Show member pathways
11.09 CRP LEP LEPR
15 10.94 ADIPOQ LEP PPARG
16 10.84 ADIPOQ LEP PPARG

GO Terms for Morbid Obesity

Cellular components related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ CCK CRP GCG GHRL INS
2 extracellular region GO:0005576 9.4 ADIPOQ CCK CRP GCG GHRL HCRT
3 secretory granule lumen GO:0034774 9.33 GCG GHRL INS

Biological processes related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.85 ADIPOQ GHRL PPARG
2 response to insulin GO:0032868 9.85 INS LEP MC4R RETN
3 G-protein coupled receptor signaling pathway GO:0007186 9.85 ADRB3 CCK GCG GHRL HCRT INS
4 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.84 ADRB3 GCG MC3R MC4R
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 ADIPOQ CCK INS
6 response to nutrient GO:0007584 9.83 ADIPOQ LEP PPARG
7 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.83 ADRB3 GCG MC3R MC4R
8 response to glucose GO:0009749 9.82 ADIPOQ INS LPL
9 glucose metabolic process GO:0006006 9.81 ADIPOQ GHRL INS LEP
10 response to nutrient levels GO:0031667 9.8 ADIPOQ GHRL INS LEP
11 regulation of blood pressure GO:0008217 9.79 LEP MC3R PPARG
12 response to cold GO:0009409 9.75 ADRB3 LPL PPARG
13 temperature homeostasis GO:0001659 9.73 ADRB3 FTO HCRT
14 glucose homeostasis GO:0042593 9.72 ADIPOQ INS LEP LEPR PPARG
15 feeding behavior GO:0007631 9.71 GCG HCRT MC4R PYY
16 positive regulation of cellular protein metabolic process GO:0032270 9.68 ADIPOQ INS
17 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 INS LEP
18 regulation of fat cell differentiation GO:0045598 9.67 LEP PPARG
19 fatty acid oxidation GO:0019395 9.66 ADIPOQ PPARG
20 sexual reproduction GO:0019953 9.65 LEP LEPR
21 negative regulation of gluconeogenesis GO:0045721 9.65 ADIPOQ INS LEPR
22 adult feeding behavior GO:0008343 9.64 GHRL LEP
23 negative regulation of blood vessel diameter GO:0097756 9.64 CRP INS
24 negative regulation of lipid storage GO:0010888 9.63 CRP LEP
25 diet induced thermogenesis GO:0002024 9.63 ADRB3 MC4R
26 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.63 ADIPOQ CRP PPARG
27 negative regulation of appetite GO:0032099 9.62 CCK LEP
28 leptin-mediated signaling pathway GO:0033210 9.62 LEP LEPR
29 regulation of bone remodeling GO:0046850 9.61 LEP LEPR
30 regulation of feeding behavior GO:0060259 9.61 LEPR MC3R MC4R
31 negative regulation of acute inflammatory response GO:0002674 9.6 INS PPARG
32 regulation of brown fat cell differentiation GO:0090335 9.59 FTO LEP
33 regulation of metabolic process GO:0019222 9.58 LEP MC4R
34 bone growth GO:0098868 9.57 LEP LEPR
35 eating behavior GO:0042755 9.56 ADRB3 CCK HCRT LEP
36 negative regulation of feeding behavior GO:2000252 9.54 INS MC4R RETN
37 regulation of signaling receptor activity GO:0010469 9.28 ADIPOQ CCK GCG GHRL HCRT INS
38 energy reserve metabolic process GO:0006112 9.26 ADRB3 LEP LEPR MC4R

Molecular functions related to Morbid Obesity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 ADIPOQ CRP GCG INS LEPR PPARG
2 neuropeptide binding GO:0042923 9.37 MC3R MC4R
3 melanocortin receptor activity GO:0004977 9.26 MC3R MC4R
4 hormone activity GO:0005179 9.23 ADIPOQ CCK GCG GHRL INS LEP
5 melanocyte-stimulating hormone receptor activity GO:0004980 9.16 MC3R MC4R
6 neuropeptide hormone activity GO:0005184 9.13 CCK HCRT PYY

Sources for Morbid Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....